



May 23, 2012

NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E)
MUMBAI -400 051

Dear Sirs,

SUB: Press Release – Reg
Ref: Our Company Code No. AUROPHARMA

Please find enclosed herewith a copy of Press Release issued by the Company.

This is for your information and record

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**


A. MOHAN RAMI REDDY
GM (Legal) & COMPANY SECRETARY

AUROBINDO PHARMA LTD

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 A.P., INDIA Tel : + + 91 40 6672 5000 Fax + + 91 40 2374 6833, 2374 1080

Corp. Off. : 'Auro House', 313, Bachupally, Quthubullapur (Mandall), RR District, Hyderabad - 500 072 A.P., INDIA Tel : + + 91 40 2304 4060-65 Fax + + 91 40 2304 4058 / 59

PAN No. AABCA7366H

www.aurobindo.com



23rd May 2012

**Aurobindo Pharma receives final approvals for
Nevirapine Tablets and Oral Suspension**

Aurobindo Pharma Limited is pleased to announce that its tentatively approved ANDAs for Nevirapine Tablets 200mg (ANDA 077521) and Nevirapine Oral Suspension 50mg/5mL (ANDA 077702) have received the final approval from the US Food & Drug Administration (USFDA). The products have a market size of approximately US\$ 125 Million for the twelve months ending December 2011 according to IMS and will be launched soon.

Nevirapine Tablets 200mg and Oral Suspension 50mg/5mL are the generic equivalent of Boehringer Ingelheim Pharmaceutical Inc's Viramune® Tablets 200mg and Oral Suspension 50mg/5mL. The products are indicated as part of antiretroviral (ARV) combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults.

Both the products have been approved out of Unit III formulations facility in Hyderabad, India.

Aurobindo now has a total of 151 ANDA approvals (125 Final approvals including 1 from Aurolife Pharma LLC and 26 Tentative approvals) from USFDA.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com